Affordable Access

deepdyve-link
Publisher Website

Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq

Authors
  • Li, Guangdi1, 2
  • Xu, Ming2
  • Yue, Tingting2
  • Gu, Weijie3
  • Tan, Li1
  • 1 Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China
  • 2 Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha 410078, China
  • 3 Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Leuven 3000, Belgium
Type
Published Article
Journal
Biochemical pharmacology
Publisher
New York, NY : Elsevier Science Inc
Publication Date
Feb 20, 2021
Volume
185
Pages
114485–114485
Identifiers
DOI: 10.1016/j.bcp.2021.114485
PMID: 33617841
PMCID: PMC7895689
Source
PubMed Central
Keywords
Disciplines
  • Review
License
Unknown

Abstract

Since the 1950s, great efforts have been made to develop antiviral agents against many infectious diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human cytomegalovirus (HCMV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). Among the list of nearly 106 antiviral agents approved in the past five decades, Prof. Erik De Clercq has contributed to the development of 7 antiviral drugs: tenofovir disoproxil fumarate (Viread®) for HIV and HBV treatment, tenofovir alafenamide (Vemlidy®) for HIV and HBV treatment, brivudine (Zostex®) for HSV-1 and VZV treatment, valacyclovir (Valtrex®) for HSV and VZV treatment, adefovir dipivoxil (Hepsera®) for HBV treatment, stavudine (Zerit®) for HIV treatment, and cidofovir (Vistide®) for treating HCMV retinitis in AIDS patients. In addition to the above antiviral drugs, his contributions include two anti-cancer drugs: rabacfosadine (Tanovea®-CA1) for canine lymphoma and plerixafor (Mozobil®) for multiple myeloma and non-Hodgkin’s lymphoma. These achievements are driven by his life-long passions for antiviral research and successful collaborations worldwide. To honor the 80th birthday of Prof. Erik De Clercq, this study highlights his scientific achievements and the importance of life-long passions and collaborations in the success of antiviral research and drug development.

Report this publication

Statistics

Seen <100 times